These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24201805)

  • 1. Murine neural stem cells model Hunter disease in vitro: glial cell-mediated neurodegeneration as a possible mechanism involved.
    Fusar Poli E; Zalfa C; D'Avanzo F; Tomanin R; Carlessi L; Bossi M; Nodari LR; Binda E; Marmiroli P; Scarpa M; Delia D; Vescovi AL; De Filippis L
    Cell Death Dis; 2013 Nov; 4(11):e906. PubMed ID: 24201805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial degeneration with oxidative damage drives neuronal demise in MPSII disease.
    Zalfa C; Verpelli C; D'Avanzo F; Tomanin R; Vicidomini C; Cajola L; Manara R; Sala C; Scarpa M; Vescovi AL; De Filippis L
    Cell Death Dis; 2016 Aug; 7(8):e2331. PubMed ID: 27512952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neural Stem Cells from Shank3-ko Mouse Model Autism Spectrum Disorders.
    Grasselli C; Carbone A; Panelli P; Giambra V; Bossi M; Mazzoccoli G; De Filippis L
    Mol Neurobiol; 2020 Mar; 57(3):1502-1515. PubMed ID: 31773410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
    Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
    J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II.
    Hong J; Cheng YS; Yang S; Swaroop M; Xu M; Beers J; Zou J; Huang W; Marugan JJ; Cai X; Zheng W
    Exp Cell Res; 2022 Mar; 412(1):113007. PubMed ID: 34990619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of polyubiquitin gene Ubb causes dysregulation of neural stem cell differentiation with premature gliogenesis.
    Ryu HW; Park CW; Ryu KY
    Sci Rep; 2014 Nov; 4():7026. PubMed ID: 25391618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
    Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
    Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS).
    Friso A; Tomanin R; Zanetti A; Mennuni C; Calvaruso F; La Monica N; Marin O; Zacchello F; Scarpa M
    Biochim Biophys Acta; 2008 Oct; 1782(10):574-80. PubMed ID: 18675343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
    Rigon L; Salvalaio M; Pederzoli F; Legnini E; Duskey JT; D'Avanzo F; De Filippis C; Ruozi B; Marin O; Vandelli MA; Ottonelli I; Scarpa M; Tosi G; Tomanin R
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
    Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
    Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
    Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shutdown of ER-associated degradation pathway rescues functions of mutant iduronate 2-sulfatase linked to mucopolysaccharidosis type II.
    Osaki Y; Saito A; Kanemoto S; Kaneko M; Matsuhisa K; Asada R; Masaki T; Orii K; Fukao T; Tomatsu S; Imaizumi K
    Cell Death Dis; 2018 Jul; 9(8):808. PubMed ID: 30042467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY; Lee J; Ko AR; Kwak MJ; Kim S; Sohn YB; Park SW; Jin DK
    Orphanet J Rare Dis; 2015 Oct; 10():141. PubMed ID: 26520066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.
    Hong SH; Chu H; Kim KR; Ko MH; Kwon SY; Moon IJ; Chung WH; Cho YS; Kim CH; Suh MW; Choi EW; Sohn YB; Park SW; Kim SH; Cho SY; Ko AR; Jin DK
    Am J Med Genet A; 2012 Sep; 158A(9):2131-8. PubMed ID: 22847837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro characterization of subventricular zone isolated neural stem cells, from adult monkey and rat brain.
    Jaberi R; Mirsadeghi S; Kiani S
    Mol Biol Rep; 2021 Feb; 48(2):1311-1321. PubMed ID: 33566222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice.
    Polito VA; Cosma MP
    Am J Hum Genet; 2009 Aug; 85(2):296-301. PubMed ID: 19679226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Hunter syndrome (mucopolysaccharidosis type II) in Taiwanese: biochemical and linkage studies of the iduronate-2-sulfatase gene defects in MPS II patients and carriers.
    Lin SP; Chang JH; Lee-Chen GJ; Lin DS; Lin HY; Chuang CK
    Clin Chim Acta; 2006 Jul; 369(1):29-34. PubMed ID: 16480701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PINK1 expression increases during brain development and stem cell differentiation, and affects the development of GFAP-positive astrocytes.
    Choi I; Choi DJ; Yang H; Woo JH; Chang MY; Kim JY; Sun W; Park SM; Jou I; Lee SH; Joe EH
    Mol Brain; 2016 Jan; 9():5. PubMed ID: 26746235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.